(BDX) Becton Dickinson - NYSE
Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NYSE (USA) | Market Cap: 39.997m USD | Total Return: 8.1% in 12m
Avg Turnover: 344M
EPS Trend: 87.0%
Qual. Beats: 1
Rev. Trend: 96.8%
Qual. Beats: 0
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products to healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical companies, and the general public. The company operates worldwide through four segments-Medical Essentials, Connected Care, BioPharma Systems, and Interventional and Life Sciences. BDX is classified within the GICS Health Care Equipment sub-industry and trades on the NYSE as a large-cap stock, reflecting its diversified product model spanning consumables, instrumentation, and specialty surgical solutions.
The companys product portfolio covers vascular access and infusion therapy systems (including peripheral and central IV catheters, needle-free connectors, closed-system drug transfer devices, and pharmacy automation), hypodermic syringes and needles, and prefillable drug delivery systems. Its diagnostics offerings include specimen and blood collection products, automated blood and tuberculosis culturing, molecular testing, microbiology laboratory automation, and flow cytometry instruments with reagents for single-cell gene expression, clinical oncology, immunology, and transplantation. BDX also provides surgical products for hernia and soft tissue repair, biosurgery, surgical infection prevention, peripheral intervention, and urology and critical care. The company maintains a strategic collaboration with ChemoGLO to advance hazardous drug contamination testing in healthcare settings, underscoring its role in medication and environmental safety for clinical environments.
- BioPharma prefillable syringes drive high-margin segment growth
- Hospital procedure volumes lift Medical Essentials and Interventional revenue
- Biosciences divestiture proceeds accelerate deleveraging and capital returns
| Net Income: 1.14b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.43 > 1.0 |
| NWC/Revenue: -2.32% < 20% (prev 4.67%; Δ -6.99% < -1%) |
| CFO/TA 0.08 > 3% & CFO 3.90b > Net Income 1.14b |
| Net Debt (16.5b) to EBITDA (4.68b): 3.51 < 3 |
| Current Ratio: 0.94 > 1.5 & < 3 |
| Outstanding Shares: last quarter (280.6m) vs 12m ago -2.96% < -2% |
| Gross Margin: 46.48% > 18% (prev 44.50%; Δ 1.98% > 0.5%) |
| Asset Turnover: 40.58% > 50% (prev 38.31%; Δ 2.27% > 0%) |
| Interest Coverage Ratio: 4.09 > 6 (EBIT TTM 2.30b / Interest Expense TTM 563.0m) |
| A: -0.01 (Total Current Assets 8.01b - Total Current Liabilities 8.51b) / Total Assets 50.8b |
| B: 0.34 (Retained Earnings 17.4b / Total Assets 50.8b) |
| C: 0.04 (EBIT TTM 2.30b / Avg Total Assets 52.6b) |
| D: 0.90 (Book Value of Equity 24.1b / Total Liabilities 26.7b) |
| Altman-Z'' = 2.29 = BBB |
| DSRI: 0.71 (Receivables 2.21b/3.03b, Revenue 21.4b/20.9b) |
| GMI: 0.96 (GM 44.50% / 46.48%) |
| AQI: 1.01 (AQ_t 0.72 / AQ_t-1 0.72) |
| SGI: 1.02 (Revenue 21.4b / 20.9b) |
| TATA: -0.05 (NI 1.14b - CFO 3.90b) / TA 50.8b) |
| Beneish M = -3.29 (Cap -4..+1) = AA |
As of June 23, 2026, the stock is trading at USD 140.71 with a total of 3,382,221 shares traded. Over the past week, the price has changed by -3.78%, over one month by -4.02%, over three months by -9.30% and over the past year by +8.05%.
Current recommended Stop Loss: 136.20 (which is 3.2% or 1.2 ATR below the current price).
Becton Dickinson has received a consensus analysts rating of 3.81. Therefore, it is recommended to buy BDX.
- StrongBuy: 6
- Buy: 1
- Hold: 9
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 180.7 | 28.4% |
P/E Trailing = 25.3333
P/E Forward = 10.7875
P/S = 1.7995
P/B = 1.6616
P/EG = 1.1074
Revenue TTM = 21.4b USD
EBIT TTM = 2.30b USD
EBITDA TTM = 4.68b USD
Long Term Debt = 14.7b USD (from longTermDebt, last quarter)
Short Term Debt = 2.57b USD (from shortTermDebt, last quarter)
Debt = 17.3b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 16.5b USD (calculated: Debt 17.3b - CCE 816.0m)
Enterprise Value = 56.5b USD (40.0b + Debt 17.3b - CCE 816.0m)
Interest Coverage Ratio = 4.09 (Ebit TTM 2.30b / Interest Expense TTM 563.0m)
EV/FCF = 17.97x (Enterprise Value 56.5b / FCF TTM 3.14b)
FCF Yield = 5.56% (FCF TTM 3.14b / Enterprise Value 56.5b)
FCF Margin = 14.71% (FCF TTM 3.14b / Revenue TTM 21.4b)
Net Margin = 5.33% (Net Income TTM 1.14b / Revenue TTM 21.4b)
Gross Margin = 46.48% ((Revenue TTM 21.4b - Cost of Revenue TTM 11.4b) / Revenue TTM)
Gross Margin QoQ = 45.69% (prev 44.63%)
Tobins Q-Ratio = 1.11 (Enterprise Value 56.5b / Total Assets 50.8b)
Interest Expense / Debt = 3.26% (Interest Expense 563.0m / Debt 17.3b)
Taxrate = 18.80% (327.0m / 1.74b)
NOPAT = 1.87b (EBIT 2.30b * (1 - 18.80%))
Current Ratio = 0.94 (Total Current Assets 8.01b / Total Current Liabilities 8.51b)
Debt / Equity = 0.72 (Debt 17.3b / totalStockholderEquity, last quarter 24.1b)
Debt / EBITDA = 3.51 (Net Debt 16.5b / EBITDA 4.68b)
Debt / FCF = 5.24 (Net Debt 16.5b / FCF TTM 3.14b)
Total Stockholder Equity = 25.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.16% (Net Income 1.14b / Total Assets 50.8b)
RoE = 4.54% (Net Income TTM 1.14b / Total Stockholder Equity 25.1b)
RoCE = 5.79% (EBIT 2.30b / Capital Employed (Equity 25.1b + L.T.Debt 14.7b))
RoIC = 4.24% (NOPAT 1.87b / Invested Capital 44.1b)
WACC = 5.85% (E(40.0b)/V(57.3b) * Re(7.24%) + D(17.3b)/V(57.3b) * Rd(3.26%) * (1-Tc(0.19)))
Discount Rate = 7.24% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -82.22 | Cagr: -1.66%
[DCF] Terminal Value 77.97% ; FCFF base≈2.92b ; Y1≈3.35b ; Y5≈4.93b
[DCF] Fair Price = 209.4 (EV 74.2b - Net Debt 16.5b = Equity 57.7b / Shares 275.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 87.00 | EPS CAGR: 7.68% | SUE: 0.96 | # QB: 1
Revenue Correlation: 96.77 | Revenue CAGR: 5.39% | SUE: 0.65 | # QB: 0
EPS current Quarter (2026-06-30): EPS=3.13 | Chg30d=+0.06% | Revisions=+47% | Analysts=11
EPS current Year (2026-09-30): EPS=12.54 | Chg30d=-0.13% | Revisions=+60% | GrowthEPS=-12.9% | GrowthRev=-12.1%
EPS next Year (2027-09-30): EPS=13.39 | Chg30d=-0.41% | Revisions=+12% | GrowthEPS=+6.8% | GrowthRev=+2.6%
[Analyst] Revisions Ratio: +60%